Format

Send to

Choose Destination
Med Sci (Paris). 2014 May;30(5):519-25. doi: 10.1051/medsci/20143005014. Epub 2014 Jun 13.

[New physiopathological roles for the PLA2R1 receptor in cancer and membranous nephropathy].

[Article in French]

Author information

1
Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France.
2
Institut de pharmacologie moléculaire et cellulaire, CNRS et université de Nice-Sophia Antipolis UMR 7275, 660 route des lucioles, Sophia Antipolis, 06560 Valbonne, France - Service de néphrologie, CHU hôpital Pasteur, université de Nice-Sophia Antipolis, Nice, France.
3
Inserm U1052, centre de recherche en cancérologie de Lyon, CNRS et université de Lyon, UMR 5286, centre Léon Bérard, 69373 Lyon, France.

Abstract

PLA2R1 is a large transmembrane receptor of 180-kDa that belongs to the superfamily of C-type lectins. It was discovered because of its high affinity for secreted phospholipases A2 (sPLA2), enzymes that play a key role in lipid mediator synthesis. Early PLA2R1 physiological roles include the clearance of sPLA2 from the extracellular medium and/or promotion of their actions. Over the last four years, two independent studies suggested that PLA2R1 plays a role in cancer as a tumor gene suppressor and is the major target antigen of auto-immune antibodies involved in idiopathic membranous nephropathy, a severe human kidney disease. These novel findings shed light on PLA2R1 and pave the way for its use as a reliable biomarker and an attractive therapeutic target in these diseases.

PMID:
24939538
DOI:
10.1051/medsci/20143005014
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center